Does Diffusely Infiltrating Lobular Carcinoma of the Breast Arise from Epithelial-Mesenchymal Hybrid Cells?
biomarkers
breast neoplasms
early detection of cancer
histopathology technology
interdisciplinary communication
mammography
neoplastic stem cell
pathologists
patient care
precision oncology
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
28 Jun 2023
28 Jun 2023
Historique:
received:
31
05
2023
revised:
19
06
2023
accepted:
26
06
2023
medline:
17
7
2023
pubmed:
14
7
2023
entrez:
14
7
2023
Statut:
epublish
Résumé
Classic diffusely infiltrating lobular carcinoma has imaging features divergent from the breast cancers originating from the terminal ductal lobular units and from the major lactiferous ducts. Although the term "invasive lobular carcinoma" implies a site of origin within the breast lobular epithelium, we were unable to find evidence supporting this assumption. Exceptional excess of fibrous connective tissue and the unique cell architecture combined with the aberrant features at breast imaging suggest that this breast malignancy has not originated from cells lining the breast ducts and lobules. The only remaining relevant component of the fibroglandular tissue is the mesenchyme. The cells freshly isolated and cultured from diffusely infiltrating lobular carcinoma cases contained epithelial-mesenchymal hybrid cells with both epithelial and mesenchymal properties. The radiologic and histopathologic features of the tumours and expression of the mesenchymal stem cell positive markers CD73, CD90, and CD105 all suggest development in the direction of mesenchymal transition. These hybrid cells have tumour-initiating potential and have been shown to have poor prognosis and resistance to therapy targeted for malignancies of breast epithelial origin. Our work emphasizes the need for new approaches to the diagnosis and therapy of this highly fatal breast cancer subtype.
Identifiants
pubmed: 37445938
pii: ijms241310752
doi: 10.3390/ijms241310752
pmc: PMC10341583
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Taiwan Association of Medical Screening
Organisme : National Research Development and Innovation Office of Hungary
ID : GINOP-2.3.2-15-2016-00020TUMORDNS
Organisme : National Research Development and Innovation Office of Hungary
ID : OTKA K125509
Organisme : National Research Development and Innovation Office
ID : OTKA PD138837
Références
J Oncol. 2019 Apr 10;2019:2087983
pubmed: 31093281
Eur J Radiol. 2022 Sep;154:110394
pubmed: 35751940
Lancet. 1985 Apr 13;1(8433):829-32
pubmed: 2858707
Lancet. 2000 Feb 5;355(9202):429-33
pubmed: 10841122
Cold Spring Harb Perspect Biol. 2012 Feb 01;4(2):
pubmed: 22300978
Cancer. 2004 Oct 15;101(8):1745-59
pubmed: 15386334
Eur J Radiol. 2022 Apr;149:110189
pubmed: 35151954
Science. 1976 Jan 23;191(4224):295-7
pubmed: 1246614
Surgery. 1946 Jan;19:74-99
pubmed: 21022022
Int J Breast Cancer. 2014;2014:581706
pubmed: 25400950
Radiology. 2021 Jun;299(3):541-547
pubmed: 33650900
Virchows Arch. 2018 Jun;472(6):1007-1014
pubmed: 29101458
Cancer. 2019 Feb 15;125(4):515-523
pubmed: 30411328
Semin Cancer Biol. 2022 Dec;87:17-31
pubmed: 36354098
Eur J Radiol. 2022 Jul;152:110323
pubmed: 35576721
Breast Cancer (Auckl). 2014 Feb 25;8:15-38
pubmed: 24653647
J Tissue Eng Regen Med. 2019 Sep;13(9):1738-1755
pubmed: 31216380
Cancer. 2020 Jul 1;126(13):2971-2979
pubmed: 32390151
Cell Stem Cell. 2019 Jan 3;24(1):65-78
pubmed: 30554963
Eur J Radiol. 2022 Aug;153:110363
pubmed: 35605334